Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world

Table 1 Patient baseline characteristics (n = 55)

Characteristics	n (%)
Age (yr)
Median	61
Range	44-74
Sex
Male	43 (78.2)
Female	12 (21.8)
Tumor location
Upper esophagus	19 (34.5)
Middle esophagus	25 (45.5)
Lower esophagus	11 (20)
Clinical stage
II	10 (18.2)
III	19 (34.5)
IV	26 (47.3)
Subgroups
Chemoradiotherapy plus pembrolizumab (group A)	21 (38.2)
Neoadjuvant therapy plus surgery (group B)	20 (36.4)
Chemotherapy plus pembrolizumab (group C)	14 (25.5)

Table 2 Summary of overall survival

	All patients (n = 55)	Group A (n = 20)	Group B (n = 21)	Group C (n = 14)
Patients with event	16 (29.1%)	8 (40.0%)	4 (19.0%)	4 (28.6%)
Patients without event	39 (70.9%)	12 (60.0%)	17 (81.0%)	10 (71.4%)
Time to event (mo)
Median	-	-	-	-
95%CI	27.0, -	9.0, -	27.0, -	12.0, -
25% and 75%-ile	15.50, -	10.50, -	27.00, -	12.50, -
Min-max	0.5-39	5-26	2.6-39	0.5-35
12 mo probability (95%CI)	78.8 (65.1-87.7)	65.0 (40.3-81.5)	95.0 (69.5-99.3)	75.0 (40.8-91.2)
18 mo probability (95%CI)	72.7 (58.3-82.9)	60.0 (35.7-77.6)	89.7 (64.8-97.3)	66.7 (33.7-86.0)

Group A: Chemoradiotherapy plus pembrolizumab. Group B: Neoadjuvant therapy plus pembrolizumab. Group C: Chemotherapy plus pembrolizumab. CI: Confidence interval.

Table 3 Summary of progression-free survival

	Group A (n = 20)	Group C (n = 14)
Patients with event	11 (55.0%)	4 (28.6%)
Patients without event	9 (45.0%)	10 (71.4%)
Time to event (mo)
Median	17	-
95%CI	8.0, -	9.0, -
25% and 75%-ile	8.50, -	12.0, -
Min-max	5-26	0.5-35
12 mo probability (95%CI)	55.0 (31.3-73.5)	67.7 (34.9-86.5)
18 mo probability (95%CI)	50.0 (27.1-69.2)	67.7 (34.9-86.5)

Group A: Chemoradiotherapy plus pembrolizumab. Group C: Chemotherapy plus pembrolizumab. CI: Confidence interval.

Table 4 Summary of disease-free survival

	Group B (n = 21)
Patients with event	7 (33.3%)
Patients without event	14 (66.7%)
Time to event (mo)
Median	-
95%CI	5.0, -
25% and 75%-ile	17.50, -
Min-max	2.6-27
12 mo probability (95%CI)	85.0 (60.4-94.9)
18 mo probability (95%CI)	75.0 (50.0-88.7)

Group B: Neoadjuvant therapy plus pembrolizumab. CI: Confidence interval.

Table 5 Patterns of recurrence and immune maintenance therapy

	Patterns of recurrence		Immune maintenance therapy
	Local	Distant organ
Group A (20)	4 (20%)	1 (5%)	10 (50%)
Group B (21)	2 (9%)	5 (24%)	3 (14.3%)
Group C (14)	2 (14.3%)	4 (28.6%)	7 (50%)

Group A: Chemoradiotherapy plus pembrolizumab. Group B: Neoadjuvant therapy plus pembrolizumab. Group C: Chemotherapy plus pembrolizumab.